Professional Documents
Culture Documents
20 49 250 mg daily
10 19 250 mg q 48 hr
For patients on hemodialysis, use 250 mg q 48 hr.
Pharmacokinetics
Route Onset Peak
Duration
Oral
Varies 1 2 hr 3 5 hr
IV
Rapid End of infusion 3 5 hr
Metabolism: Hepatic; T1/2: 4 7 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Urine
IV facts
Preparation: No further preparation is needed if using the premixed solution; di
lute single-use vials in 50 100 mL D5W.
Infusion: Administer slowly over at least 60 90 min. Do not administer IM or subcu
taneously.
Compatibilities: Can be further diluted in 0.9% sodium chloride injection, 5% de
xtrose injection, 5% dextrose/0.9% sodium chloride, 5% dextrose in lactated Ring
er's, Plasma-Lyte 56 and 5% Dextrose injection, 9% dextrose/0.45% sodium chlorid
e, 0.15% potassium chloride, sodium lactate injection.
Adverse effects
CNS: Headache, dizziness, insomnia, fatigue, somnolence, blurred vision
GI: Nausea, vomiting, dry mouth, diarrhea, abdominal pain (occur less wit
h this drug than with oflaxacin), constipation, flatulence
Hematologic: Elevated BUN, AST, ALT, serum creatinine, and alkaline phosp
hatase; neutropenia, anemia
Other: Fever, rash, photosensitivity, muscle and joint tenderness, increa
sed serum glucose
Interactions
Drug-drug
Decreased therapeutic effect with iron salts, sulcrafate, antacids, zinc,
magnesium (separate by at least 2 hr)
Increased risk of seizures with NSAIDs; avoid this combination
Drug-alternative therapy
Increased risk of severe photosensitivity reactions if combined with St.
John's wort therapy
Nursing considerations
Assessment
History: Allergy to fluoroquinolones, renal dysfunction, seizures, lactat
ion, pregnancy
Physical: Skin color, lesions; T; orientation, reflexes, affect; mucous m
embranes, bowel sounds; renal and liver function tests; blood glucose (diabetics
)
Interventions
Arrange for culture and sensitivity tests before beginning therapy.
Continue therapy as indicated for condition being treated.
Administer oral drug 1 hr before or 2 hr after meals with a glass of wate
r; separate oral drug from other cation administration, including antacids, by a
t least 2 hr.
Ensure that patient is well hydrated during course of therapy.
WARNING: Discontinue drug at any sign of hypersensitivity (rash, photopho
bia) or at complaint of tendon pain, inflammation, or rupture.
Monitor clinical response; if no improvement is seen or a relapse occurs,
repeat culture and sensitivity test.
Teaching points
Take oral drug on an empty stomach, 1 hr before or 2 hr after meals. If a
n antacid is needed, do not take it within 2 hr of levofloxacin dose.
Drink plenty of fluids while you are using this drug.
You may experience these side effects: Nausea, vomiting, abdominal pain (
eat frequent small meals); diarrhea or constipation (consult nurse or physician)
; drowsiness, blurred vision, dizziness (use caution if driving or operating dan
gerous equipment); sensitivity to sunlight (avoid exposure, use a sunscreen if n
ecessary).
Report rash, visual changes, severe GI problems, weakness, tremors.
Adverse effects in Italic are most common; those in Bold are life-threatening.